目的 評價舒肝解郁膠囊聯(lián)合帕羅西汀治療精神分裂癥后抑郁的治療效果。方法 采用隨機方法將100例精神分裂癥后抑郁患者分為治療組(舒肝解郁膠囊與帕羅西汀合用)和對照組(單用帕羅西汀)各50例。兩組患者口服帕羅西汀初始劑量為10～20 mg/d, 逐漸加至20～40 mg/d。治療組在應用帕羅西汀的同時, 加服舒肝解郁膠囊1.44 g/d, 療程8周。分別在治療前及治療2、4、8周后采用漢密爾頓抑郁量表(HAMD)和副反應量表(TESS)對兩組患者進行療效及不良反應評定。結(jié)果 治療2、4、8周后兩組HAMD評分均比治療前明顯下降, 且治療組評分顯著低于對照組(P<0.05)。TESS評分兩組間差異無顯著性。治療組的顯效率90%顯著高于對照組的顯效率74%(P<0.05)。結(jié)論 舒肝解郁膠囊聯(lián)合帕羅西汀治療精神分裂癥后抑郁療效好于單用帕羅西汀治療, 未見不良反應增加。

Objective To compare the effect of Shugan Jieyu Capsule plus Paroxetine in the treatment of past-schizophrenia depression. Methods One hundred patients with past-schizophrenia depression were randomly divided into a study group (treated with Shugan Jieyu Capsule plus Paroxetine) and a control group (treated with Paroxetine only) equally. The treatment course is 8 weeks. At first, the initial dose of Paroxetine was 10—20 mg/d, gradually increased to 20—40 mg/d. At the same time, the patients in the study groups were added to take Shugan Jieyu Capsule 1.44g/d. When the patients were grouped, evaluating the patients in two groups in the aspects of the clinical effect and side effects with Hamilton's depression scale (HAMD) and treatment emergent symptom scale (TESS). In addition, after 2, 4, and 8 weeks, the patients in the aspects of the clinical effect and side effects with HAMD and TESS were re-evaluated. Results After 2, 4, and 8 weeks, the HAMD scores of patients in both groups were more significantly decreased than the beginning, and the scores of the patients in the study group were lower than those of the patients in the control group (P<0.05). The TESS scores between the two groups had no significant difference (P>0.05). The study group showed the effective rate of 90% which was significantly higher than 74% of the control group (P<0.05). Conclusion Shugan Jieyu Capsule plus Paroxetine has better effect in the treatment of past-schizophrenia depression, the adverse reaction is not increasing.